River Street Advisors LLC Has $1.63 Million Stock Position in Zoetis Inc. $ZTS

River Street Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 207.3% in the third quarter, HoldingsChannel.com reports. The firm owned 11,105 shares of the company’s stock after purchasing an additional 7,491 shares during the quarter. River Street Advisors LLC’s holdings in Zoetis were worth $1,625,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Zoetis in the 2nd quarter valued at $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the period. Corient Private Wealth LLC lifted its holdings in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after buying an additional 1,191,840 shares during the period. Impax Asset Management Group plc boosted its position in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares during the last quarter. Finally, Swedbank AB grew its holdings in Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after acquiring an additional 917,598 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research note on Monday, December 15th. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, UBS Group cut their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $160.18.

Zoetis Trading Down 0.0%

NYSE ZTS opened at $125.77 on Monday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40. The business has a 50 day moving average price of $125.02 and a 200-day moving average price of $141.51. The company has a market cap of $55.43 billion, a price-to-earnings ratio of 21.17, a P/E/G ratio of 2.57 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period last year, the business earned $1.58 EPS. Zoetis’s quarterly revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio is 33.67%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.